MEDFORD, N.Y., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today announced that its chief executive officer, John J. Sperzel III, will present a corporate update at the 7 th Annual Biotech Showcase
MEDFORD, N.Y., Jan. 6, 2015 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has entered into an agreement with the Concussion Science Group (CSG) Division of Perseus Science Group LLC, to
MEDFORD, N.Y. , Nov. 24, 2014 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has entered into a follow-on, milestone-based development agreement with a private contracting organization
Category: Baystreet Newswire Company: Issuer Direct ID: 422546 Date: Wednesday, November 05, 2014 Ticker: NASDAQ:CEMI MEDFORD, NY / ACCESSWIRE / November 5, 2014 / Chembio Diagnostics, Inc. (NASDAQ: CEMI) will host a conference call and live webcast to discuss the results of the third quarter 2014,
MEDFORD, N.Y., Oct. 28, 2014 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that on October 27, 2014 it entered into an agreement to develop a POC diagnostic test for dengue fever virus.
MEDFORD, N.Y., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has entered into an exclusive agreement with Integrated BioTherapeutics, Inc. (IBT), a biotechnology company
Print Page